Comparative Pharmacology
Head-to-head clinical analysis: REVUFORJ versus VIVJOA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVUFORJ versus VIVJOA.
REVUFORJ vs VIVJOA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
VIVJOA (fosmanogepix) is a first-in-class antifungal agent that inhibits the fungal enzyme Gwt1, which is involved in glycosylphosphatidylinositol (GPI) anchor biosynthesis. This disrupts cell wall integrity and fungal growth.
Oral, 500 mg twice daily.
VIVJOA (750 mg tablet) is administered as a single oral dose of 750 mg, taken once daily for 6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Terminal elimination half-life is approximately 20–26 hours, supporting once-daily dosing for sustained therapeutic levels.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Primarily hepatic metabolism via CYP3A4, with <1% excreted unchanged in urine; fecal elimination accounts for approximately 88% of the administered dose as metabolites.
Category C
Category C
JAK Inhibitor
JAK Inhibitor